- Home
- AMBI vs CLLS Comparison
AMBI vs CLLS Comparison
Compare AMBI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBI
- CLLS
- Stock Information
- Founded
- AMBI 1995
- CLLS 1999
- Country
- AMBI Brazil
- CLLS France
- Employees
- AMBI N/A
- CLLS N/A
- Industry
- AMBI Environmental Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AMBI Industrials
- CLLS Health Care
- Exchange
- AMBI Nasdaq
- CLLS Nasdaq
- Market Cap
- AMBI 255.0M
- CLLS 240.2M
- IPO Year
- AMBI N/A
- CLLS 2007
- Fundamental
- Price
- AMBI $5.75
- CLLS $1.99
- Analyst Decision
- AMBI
- CLLS Buy
- Analyst Count
- AMBI 0
- CLLS 2
- Target Price
- AMBI N/A
- CLLS $8.00
- AVG Volume (30 Days)
- AMBI 6.0K
- CLLS 23.2K
- Earning Date
- AMBI 01-01-0001
- CLLS 11-04-2024
- Dividend Yield
- AMBI N/A
- CLLS N/A
- EPS Growth
- AMBI 3161.09
- CLLS N/A
- EPS
- AMBI 0.56
- CLLS N/A
- Revenue
- AMBI $504,573,816.00
- CLLS $19,635,000.00
- Revenue This Year
- AMBI N/A
- CLLS $271.02
- Revenue Next Year
- AMBI N/A
- CLLS $33.48
- P/E Ratio
- AMBI $9.84
- CLLS N/A
- Revenue Growth
- AMBI 25.13
- CLLS N/A
- 52 Week Low
- AMBI $3.07
- CLLS $0.96
- 52 Week High
- AMBI $8.44
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- AMBI 62.31
- CLLS 42.28
- Support Level
- AMBI $4.99
- CLLS $1.88
- Resistance Level
- AMBI $6.02
- CLLS $2.07
- Average True Range (ATR)
- AMBI 0.44
- CLLS 0.10
- MACD
- AMBI 0.07
- CLLS -0.02
- Stochastic Oscillator
- AMBI 65.99
- CLLS 31.94
About AMBI Ambipar Emergency Response
Ambipar Emergency Response is a environmental, emergency response and industrial field service provider in Brazil with presence in 16 countries in Latin America, North America, Europe, Africa and Antarctica. The company provides customers with a full suite of environmental services organized around prevention, training and emergency response on all transportation modes. The portfolio includes a broad variety of services such as environmental remediation, industrial field services, industrial cleaning of chemical and non-chemical products and of hazardous and non-hazardous waste, consulting services focused on accident prevention and environmental licensing.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.